A detailed history of Swiss National Bank transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Swiss National Bank holds 207,600 shares of CPRX stock, worth $4.75 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
207,600
Previous 208,800 0.57%
Holding current value
$4.75 Million
Previous $3.23 Million 27.61%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

SELL
$15.19 - $21.35 $18,228 - $25,620
-1,200 Reduced 0.57%
207,600 $4.13 Million
Q1 2024

May 07, 2024

BUY
$13.18 - $17.11 $259,646 - $337,067
19,700 Added 10.42%
208,800 $3.33 Million
Q4 2023

Feb 06, 2024

SELL
$11.78 - $17.29 $393,452 - $577,486
-33,400 Reduced 15.01%
189,100 $3.18 Million
Q3 2023

Nov 08, 2023

BUY
$11.69 - $15.02 $46,760 - $60,080
4,000 Added 1.83%
222,500 $2.6 Million
Q2 2023

Aug 09, 2023

BUY
$11.5 - $18.08 $58,650 - $92,207
5,100 Added 2.39%
218,500 $2.94 Million
Q1 2023

May 10, 2023

SELL
$14.34 - $21.05 $322,650 - $473,625
-22,500 Reduced 9.54%
213,400 $3.54 Million
Q4 2022

Feb 08, 2023

BUY
$12.25 - $19.5 $51,450 - $81,900
4,200 Added 1.81%
235,900 $4.39 Million
Q1 2022

May 09, 2022

BUY
$5.31 - $8.31 $75,933 - $118,833
14,300 Added 6.58%
231,700 $1.92 Million
Q2 2021

Aug 06, 2021

SELL
$4.29 - $6.05 $32,604 - $45,980
-7,600 Reduced 3.38%
217,400 $1.25 Million
Q1 2021

May 07, 2021

BUY
$3.45 - $4.69 $19,665 - $26,733
5,700 Added 2.6%
225,000 $1.04 Million
Q2 2020

Aug 05, 2020

BUY
$3.48 - $5.05 $137,112 - $198,970
39,400 Added 21.9%
219,300 $1.01 Million
Q1 2020

May 08, 2020

BUY
$2.61 - $5.21 $6,786 - $13,546
2,600 Added 1.47%
179,900 $693,000
Q4 2019

Feb 06, 2020

BUY
$3.67 - $5.7 $19,084 - $29,640
5,200 Added 3.02%
177,300 $665,000
Q2 2019

Aug 02, 2019

BUY
$2.7 - $6.11 $464,670 - $1.05 Million
172,100 New
172,100 $661,000

Others Institutions Holding CPRX

About CATALYST PHARMACEUTICALS, INC.


  • Ticker CPRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 102,820,000
  • Market Cap $2.35B
  • Description
  • Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...
More about CPRX
Track This Portfolio

Track Swiss National Bank Portfolio

Follow Swiss National Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

News

Stay updated on Swiss National Bank with notifications on news.